A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

Stopped early · Phase 1

Conditions studied: Locally Advanced Malignant Neoplasm, Metastatic Cancer

In brief

The purpose of this study is to test the safety and efficacy of OMP-336B11. OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.

Key facts

Study ID
NCT03295942
Run by
OncoMed Pharmaceuticals, Inc.
People needed
24
Starts
2017-09-12
Expected to finish
2019-07-04
Last updated by the study team
2020-08-11

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.